Rani Therapeutics (RANI)
(Real Time Quote from BATS)
$2.25 USD
+0.07 (3.21%)
Updated Sep 24, 2024 02:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Rani Therapeutics Holdings, Inc. [RANI]
Reports for Purchase
Showing records 1 - 20 ( 47 total )
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Financial Results; Lowering PT to $9 on Equity Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
New Partnership Launches Rani Into Oral GLP-1/GLP-2 Race; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Financial Results; Raising PT to $13; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage; Acquisition by Pathos AI Completed
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Our Takes from Positive RT-111 Data; 2023 Financials; Lowering PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
RaniPill Delivers in 3rd Ph1 w/ Stelara Biosim; Mgmt Webinar on Feb. 8 @ 11A ET
Provider: Wedbush Securities Inc.
Analyst: ANDERSON R
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Rani Therapeutics Management Access Webinar Invite - Feb. 8, 2024 at 11AM ET
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term RaniPill- Catalysts Ahead; 3Q23 Financials; Lowering PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Focusing on RT-102, RT-111, RaniPill HC Manufacturing; Runway into 2025
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Update Extends Runway Through Key Inflection Points; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Mounting Data Supports Favorable RaniPill- Safety Profile; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Humira Reliably Delivered Via Oral RaniPill- in Canine Model; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Successful Delivery Via Next-Gen, High-Capacity RaniPill; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Q2: RT-102 RT-111 Become the Focus for 2023, Celltrion Partnership Expansion
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
RaniPill to Enter Phase 2 in 2H23; 2Q23 Financials; Modulating PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M